Effect of creatinine clearance on patterns of toxicity in older patients receiving adjuvant chemotherapy for breast cancer

被引:25
|
作者
Hurria, A [1 ]
Hurria, A [1 ]
Brogan, K [1 ]
Panageas, KS [1 ]
Pearce, C [1 ]
Norton, L [1 ]
Jakubowski, A [1 ]
Howard, J [1 ]
Hudis, C [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
关键词
D O I
10.2165/00002512-200522090-00007
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Objective: A number of age-related physiological changes contribute to an increased risk of toxicity of cancer chemotherapy in the elderly. One of the most important of these changes is the progressive decline in renal function with aging. We sought to determine the association between calculated creatinine clearance (CLCR) and grade 3 or 4 toxicities during adjuvant chemotherapy in women >= 65 years of age with breast cancer. Design and methods: We identified 1405 patients >= 65 years of age who had been treated for primary invasive breast cancer at Memorial Sloan-Kettering Cancer Center between January 1998 and December 2000. Patients were included in this analysis if they had stage I-III breast cancer and had received adjuvant chemotherapy. Patients were excluded if they had a prior history of breast cancer or chemotherapy, or had no baseline creatinine value available for review. Results: The 126 patients who met our criteria had received either cyclophosphamide, methotrexate and fluorouracil (CMF) [n = 65, mean age 7 1, range 65-78] or an anthracycline-based regimen (n = 61, mean age 69, range 65-79). The majority of patients (97%) had a normal creatinine. CLCR, as calculated by the Cockcroft-Gault and Jeliffe formulas, decreased with increasing age (increased age associated with decreased Cockcroft-Gault [p = 0.02]; increased age associated with decreased Jeliffe [p < 0.01]). In multivariate analysis, after controlling for age and co-morbidity, a CLCR <50 mL/min by the Cockcroft-Gault formula was associated with an increased risk of fever and neutropenia (odds ratio [OR] 3.60; 95% CI 1.00, 12.94; p = 0.05) and a CLCR <50 mL/min by the Jeliffe formula was associated with a trend towards an increased risk of fever and neutropenia (OR 3.30; 95% CI 0.91, 12.33; p = 0.07), grade 3 or 4 haematological toxicity (OR 2.43; 95% CI 0.90, 6.55; p = 0.08), and need for erythropoietin (OR 4.15; 95% CI 0.81, 2.99; p = 0.09). An increase in creatinine (as a continuous variable) was associated with a trend towards an increased risk of grade 3 or 4 haematological toxicity (OR 5.81; 95% CI 0.96, 35.33; p = 0.06). Conclusions: In this cohort of older breast cancer patients, a decreased CLCR and increased creatinine was associated with an increased risk of fever and neutropenia or haematological toxicity. CLCR should be considered when determining chemotherapy dosage in the elderly.
引用
收藏
页码:785 / 791
页数:7
相关论文
共 50 条
  • [41] LYMPHOCYTE CYTOGENETICS IN BREAST-CANCER PATIENTS RECEIVING ADJUVANT CHEMOTHERAPY
    STEPHAN, EJ
    TATTERSALL, MHN
    BAKER, RSU
    GILLIES, CB
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 1983, 10 (04) : 434 - 434
  • [42] Energy balance in early breast cancer patients receiving adjuvant chemotherapy
    Harvie, MN
    Campbell, IT
    Baildam, A
    Howell, A
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 83 (03) : 201 - 210
  • [43] Effect of immunomodulator "Poloxydony" on breast cancer patients' quality of life receiving the adjuvant FAC chemotherapy
    Komarova, L. E.
    Manzyuk, L. V.
    Artamonova, E. V.
    Yudina, S. V.
    ANNALS OF ONCOLOGY, 2004, 15 : 67 - 68
  • [44] The Cardioprotective Effect of Vitamin D in Breast Cancer Patients Receiving Adjuvant Doxorubicin Based Chemotherapy
    El-Bassiouny, Noha A.
    Helmy, Maged W.
    Hassan, Mostafa Alaa Eldin
    Khedr, Gehan A.
    CLINICAL BREAST CANCER, 2022, 22 (04) : 359 - 366
  • [45] DETERMINATION OF CREATININE CLEARANCE (C-CRN) IN PATIENTS RECEIVING CHEMOTHERAPY
    ROBINSON, B
    NEW ZEALAND MEDICAL JOURNAL, 1989, 102 (868) : 257 - 257
  • [46] TOXICITY OF ADJUVANT CHEMOTHERAPY OF BREAST-CANCER
    GLASS, A
    WIEAND, S
    FISHER, B
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1980, 21 (MAR): : 404 - 404
  • [47] A prospective, longitudinal study of the functional status and quality of life of older patients with breast cancer receiving adjuvant chemotherapy
    Hurria, Arti
    Hurria, Anju
    Zuckerman, Enid
    Panageas, Katherine S.
    Fornier, Monica
    D'Andrea, Gabriella
    Dang, Chau
    Moasser, Mark
    Robson, Mark
    Seidman, Andrew
    Currie, Violante
    VanPoznak, Catherine
    Theodoulou, Maria
    Lachs, Mark S.
    Hudis, Clifford
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2006, 54 (07) : 1119 - 1124
  • [48] Adjuvant Chemotherapy of Breast Cancer in the Older Patient
    Taylor, W. Chris
    Muss, Hyman B.
    ONCOLOGY-NEW YORK, 2010, 24 (07): : 608 - 613
  • [49] Adjuvant Chemotherapy for Breast Cancer in Older Women
    Spurrell, E.
    Wilson, P.
    Gallagher, C.
    Slater, S.
    Roylance, R.
    CLINICAL ONCOLOGY, 2016, 28 (08) : 542 - 542
  • [50] Adjuvant chemotherapy of older women with breast cancer
    Muss, H. B.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2007, 64 : S17 - S18